MorphoSys AG (NASDAQ:MOR) has received a consensus rating of “Hold” from the fourteen ratings firms that are presently covering the firm, Marketbeat Ratings reports. Ten investment analysts have rated the stock with a hold rating and four have given a buy rating to the company. The average 12 month price target among brokerages that have issued ratings on the stock in the last year is $28.17.
Several brokerages have weighed in on MOR. JPMorgan Chase & Co. reaffirmed a “neutral” rating on shares of MorphoSys in a research report on Wednesday, August 4th. Deutsche Bank Aktiengesellschaft cut MorphoSys from a “buy” rating to a “hold” rating in a research note on Thursday, August 5th. Citigroup cut MorphoSys from a “buy” rating to a “neutral” rating in a research note on Monday, September 27th. Morgan Stanley reissued an “overweight” rating on shares of MorphoSys in a research note on Wednesday, August 4th. Finally, Commerzbank cut MorphoSys from a “buy” rating to a “hold” rating and set a $59.00 price target for the company. in a research note on Tuesday, July 27th.
A number of hedge funds have recently made changes to their positions in the stock. BlackRock Inc. bought a new position in MorphoSys during the first quarter valued at about $73,000. Capital Asset Advisory Services LLC boosted its stake in MorphoSys by 45.2% during the first quarter. Capital Asset Advisory Services LLC now owns 11,918 shares of the company’s stock valued at $260,000 after buying an additional 3,709 shares in the last quarter. Geneos Wealth Management Inc. bought a new position in MorphoSys during the first quarter valued at about $105,000. Envestnet Asset Management Inc. boosted its stake in MorphoSys by 17.2% during the first quarter. Envestnet Asset Management Inc. now owns 30,533 shares of the company’s stock valued at $666,000 after buying an additional 4,492 shares in the last quarter. Finally, Millennium Management LLC boosted its stake in MorphoSys by 4.0% during the first quarter. Millennium Management LLC now owns 188,198 shares of the company’s stock valued at $4,103,000 after buying an additional 7,177 shares in the last quarter. 1.71% of the stock is owned by institutional investors and hedge funds.
MorphoSys (NASDAQ:MOR) last issued its earnings results on Wednesday, July 28th. The company reported $0.18 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.48) by $0.66. MorphoSys had a negative return on equity of 16.50% and a negative net margin of 68.05%. The firm had revenue of $46.06 million for the quarter, compared to analyst estimates of $46.02 million. Equities analysts forecast that MorphoSys will post -1.78 EPS for the current fiscal year.
MorphoSys AG engages in the development of antibodies for therapeutic, diagnostics, and research applications. It operates through the Proprietary Development and Partnered Discovery segments. The Proprietary Development segment combines proprietary research and development of therapeutic compounds. The Partnered Discovery segment offers technologies to make human antibody-based therapeutics on behalf of partners in the pharmaceutical industry.
Recommended Story: What is the accumulation/distribution indicator?
Receive News & Ratings for MorphoSys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MorphoSys and related companies with MarketBeat.com's FREE daily email newsletter.